Stocks · Healthcare · Biotechnology
Indaptus Therapeutics, Inc. INDP
$2.38 +12.26% Close, Oct 2, 2026 · NASDAQ · Market cap $269.5M
High risk
Next earnings report: Nov 17, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 20099.4% in a year.
- Earnings beat analyst estimates in each of the last 6 quarters (average surprise over the last four: +61.0%).
- The stock is 50% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 7%
- Accruals (lower is better)Bottom 24%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 1%
- Free-cash-flow yieldBottom 48%
- EBITDA / enterprise valueBottom 47%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 2%
- 6-month returnTop 20%
- 1-year return vs S&P 500Bottom 21%
- Distance from 52-week highBottom 16%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 10%
- Consecutive EPS beatsTop 12%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 2%
- Maximum drawdown, 3 yearsBottom 1%
- Beta vs S&P 500 (lower is better)Bottom 37%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -129.9% | — | Bottom 7% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -2.0%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -7.72%
- Shareholder yield
- -7.72%
- Share count change, 1 year
- +20099.4%
- Share count change, 3-year CAGR
- +628.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 13, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 6
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- +61.0%
- Average 2-day reaction, last 8
- +1.1%
- Positive 20 days after report
- 3 of 8
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | +98.7% | +3.9% | -7.8% | +151.0% | — |
| May 15, 2026 | +87.7% | -9.1% | -39.4% | +104.6% | -32.0% |
| Mar 17, 2026 | +28.9% | +12.0% | -1.1% | +33.1% | +40.0% |
| Nov 12, 2025 | +28.5% | +6.3% | -15.1% | -2.6% | -33.8% |
| Aug 11, 2025 | +9.8% | +8.8% | -0.7% | -59.4% | -56.5% |
| May 14, 2025 | +22.0% | -3.7% | -10.1% | -21.6% | -41.8% |
| Mar 13, 2025 | -2318.2% | -4.0% | -8.3% | -39.6% | -59.1% |
| Nov 12, 2024 | -1806.4% | -5.0% | -9.1% | -17.4% | -32.2% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.02 | -$1.57 | +98.7% | — |
| May 15, 2026 | -$0.23 | -$1.87 | +87.7% | — |
| Mar 17, 2026 | -$3.10 | -$4.36 | +28.9% | — |
| Nov 12, 2025 | -$2.98 | -$4.17 | +28.5% | — |
| Aug 11, 2025 | -$9.09 | -$10.08 | +9.8% | — |
| May 14, 2025 | -$8.96 | -$11.48 | +22.0% | — |
| Mar 13, 2025 | -$10.64 | -$0.44 | -2318.2% | — |
| Nov 12, 2024 | -$8.96 | -$0.47 | -1806.4% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -5.63% | — | — | Bottom 48% |
| Earnings yield | -292.67% | — | — | Bottom 1% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 19
- Days above the 200-day average
- 1
- 50-day average slope (20 days)
- +4.5%
- 200-day average slope (20 days)
- +3.5%
- Distance from 50-day average
- +21.0%
- Distance from 200-day average
- +4.9%
- RSI (14)
- 46.9
- Relative volume
- 0.35×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 201.0%
- Volatility vs own 5-year history
- 95th percentile · High for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.35
- Correlation with S&P 500
- 0.12
- Current drawdown from 1-year high
- -49.9%
- Maximum drawdown, 3 years
- -98.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 10, 2021 | Aug 18, 2026 | -99.9% | 1385 days | Not yet recovered |
| Oct 8, 2020 | Oct 30, 2020 | -59.1% | 16 days | 68 days (Feb 9, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $269.5M
- EPS, diluted (TTM)
- -$6.97
- Revenue (TTM)
- $0
- 52-week range
- $0.92 – $5.96
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$7.7M | -$14.9M | -$16.4M | -$15.4M | -$19.8M |
| Net income | -$7.7M | -$14.3M | -$15.4M | -$15.0M | -$20.8M |
| EPS (diluted) | -$52.78 | -$48.54 | -$51.41 | -$44.96 | -$21.58 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.1M | -$4.1M | -$4.5M | -$5.2M | -$3.0M | -$8.1M | -$2.5M | -$1.8M |
| EPS (diluted) | -$9.04 | -$10.43 | -$9.00 | -$9.10 | -$2.98 | -$3.74 | -$0.23 | -$0.02 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$11.3M | -$13.1M | -$13.4M | -$12.3M | -$14.8M |
| Capital expenditure | -$3,854 | -$172,555 | $0 | $0 | -$4 |
| Free cash flow | -$11.3M | -$13.3M | -$13.4M | -$12.3M | -$14.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $5.0M | $0 | $0 | $5.5M | $11.8M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $11.6M
- Total assets
- $12.0M
- Total liabilities
- $615,426
- Total debt
- $0
- Net debt
- -$7.6M
- Shareholders’ equity
- $11.4M
As of Jun 30, 2026 (filed Aug 13, 2026).
Short interest
- Shares sold short
- 916,352
- Days to cover
- 1.00
- Change vs previous report
- +331.5%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jun 27, 2025
- 1-for-28
- Jul 27, 2021
- 1-for-4
- Oct 30, 2020
- 1-for-20